查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530795

2030 年医药市场预测：按产品类型、给药途径、治疗领域、最终用户和地区进行的全球分析

Pharmaceuticals Market Forecasts to 2030 - Global Analysis By Product Type (Branded Drugs, Generic Drugs, OTC Drugs, Biopharmaceuticals, Vaccines and Other Product Types), Route of administration, Therapy Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球医药市场规模将达到 16 亿美元，预计 2030 年将达到 26 亿美元，预测期内复合年增长率为 8.4%。

药品是为诊断、治疗、预防和缓解疾病而开发的药物。该领域涵盖新化合物从发现到开发、测试、监管核准、生产和分销的整个过程。药品包括多种产品，从非处方药到处方药、疫苗和生技药品。该行业受到严格监管，需要进行广泛的研究、临床试验并遵守 FDA 等权威机构制定的标准，以确保药品的安全性、有效性和品质。药物在现代医疗保健中发挥重要作用，可以管理各种健康状况，改善患者的治疗效果，并为公共卫生做出贡献。

慢性病增加

慢性病盛行率的不断上升推动了对持续用药、专门治疗和创新治疗的需求，从而导致製药公司的销售和收益增加。这一趋势也刺激了研发投资，促进了新药和改良药物的创造。此外，业界为应对复杂的健康挑战而建立的联盟和合作也在不断发展，从而促进了市场成长。

药价上涨的社会监测

公众监督可能会导致监管压力和旨在遏製或降低药品价格的立法行动增加。它还可能导致声誉受损并影响股价和投资者信心。公司可能面临较低的利润率，从而阻碍新药研发的投资并阻碍预测期内的成长。

政府增加医疗保健支出

政府投资的增加将加强医疗基础设施并支持基本药物的广泛分配，从而增加製药公司的需求和销售。它还资助研究和开发倡议，并促进创新和新治疗方法的引进。此外，政府支出通常包括津贴和报销计划，使患者更能负担得起药品并促进市场成长。

学名药竞争

当品牌药的专利到期时，学名药製造商能够生产和销售品牌药的廉价版本，导致品牌药的销售量急剧下降。学名药的存在迫使品牌药品製造商在行销和创新方面投入更多资金，以实现产品差异化，从而增加营运成本。

COVID-19 的影响：

COVID-19大流行对医药市场产生了重大影响，加速了技术创新以及疫苗和治疗方法的发展。它增加了对药物、诊断和医疗保健用品的需求，提高了许多公司的收益。但它也扰乱了供应链、推迟了临床试验并导致资源紧张。这场危机凸显了该行业敏捷性和协作的重要性，从而导致快速进展并重新关注全球卫生准备和抵御未来流行病的能力。

品牌药品市场预计在预测期内成为最大的市场

品牌药品受专利保护，使製药公司能够收回研发成本并为进一步创新提供资金。品牌药品通常价格高昂，为製造商带来可观的收益和利润，对于推进治疗方法和解决未满足的医疗保健需求至关重要。

癌症领域预计在预测期内复合年增长率最高

由于全球癌症发生率高，对有效治疗的需求不断增加，使得肿瘤学成为製药公司的首要任务。这种关注导致了标靶治疗、免疫疗法和个人化医疗等创新治疗方法的发展，这些疗法价格高昂，并产生可观的收益，确保了行业内的持续成长和创新。

占比最大的地区：

预计北美在预测期内将占据最大的市场占有率北美，尤其是美国，占据全球医药市场的大部分。该市场的特点是人口老化、慢性病盛行率上升以及对创新治疗的高需求推动的强劲增长。此外，该地区是医药创新领域的领导者，并在研发方面投入大量资金。

复合年增长率最高的地区：

预计亚太地区在预测期内将保持最高的复合年增长率，因为由于医疗保健需求的增加、可支配收入的增加和医疗保健服务范围的扩大，该地区正在显着增长。中国和印度等国家因其庞大的人口和发达的医疗基础设施而对这一增长做出了重大贡献。当地企业是学名药市场的主要参与者，为该地区製药业的成长做出了贡献。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球医药市场：依产品类型

  • 品牌药品
  • 学名药
  • 非处方药
  • 生物製药
  • 疫苗
  • 其他产品类型

第六章全球医药市场：依途径

  • 口服
    • 锭剂
    • 胶囊
    • 液体
    • 糖浆
  • 注射
    • 静脉
    • 肌肉注射
    • 皮下的
    • 滴
  • 话题
    • 奶油
    • 软膏
    • 凝胶
    • 修补
  • 吸入
    • 定量吸入器
    • 干粉吸入器
    • 喷雾器
  • 经皮的
  • 鼻腔
  • 其他给药途径

第七章全球医药市场：依治疗领域

  • 肿瘤学
  • 心血管疾病
  • 神经病学
  • 呼吸系统疾病
  • 胃肠道疾病
  • 感染疾病
  • 糖尿病
  • 其他治疗领域

第八章全球製药市场：依最终用户分类

  • 诊所
  • 医院
  • 居家照护环境
  • 研究/学术机构
  • 其他最终用户

第九章全球医药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 公司概况

  • Pfizer Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Novartis International AG
  • Merck & Co., Inc.（MSD）
  • Bristol-Myers Squibb
  • Sanofi
  • GlaxoSmithKline
  • AstraZeneca
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim
  • Gilead Sciences, Inc.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Biogen Inc.
Product Code: SMRC26907

According to Stratistics MRC, the Global Pharmaceuticals Market is accounted for $1.6 billion in 2024 and is expected to reach $2.6 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Pharmaceuticals are drugs and medications developed for use in medical diagnosis, treatment, prevention, and alleviation of diseases. This field encompasses the entire process from the discovery of new compounds to their development, testing, regulatory approval, production, and distribution. Pharmaceuticals include a wide range of products, from over-the-counter drugs to prescription medications, vaccines, and biologics. The industry is highly regulated to ensure drug safety, efficacy, and quality, requiring extensive research, clinical trials, and adherence to standards set by authorities like the FDA. Pharmaceuticals play a critical role in modern healthcare, enabling the management of various health conditions, enhancing patient outcomes, and contributing to public health.

Market Dynamics:

Driver:

Increasing incidence of chronic diseases increases

Increasing incidence of chronic diseases drives demand for ongoing medication, specialized treatments, and innovative therapies, leading to higher sales and revenue growth for pharmaceutical companies. This trend also stimulates research and development investments, fostering the creation of new and improved drugs. Additionally, it encourages partnerships and collaborations within the industry to address complex health challenges propelling the markets growth.

Restraint:

Public scrutiny of high drug prices

Public scrutiny can lead to increased regulatory pressure and legislative actions aimed at controlling or reducing drug prices. It may also result in reputational damage, affecting stock prices and investor confidence. Companies might face reduced profit margins, hampering their ability to invest in research and development for new drugs hampering its growth during the forecast period.

Opportunity:

Increased government spending on healthcare

Increased government nvestment enhances healthcare infrastructure and supports broader distribution of essential drugs, driving higher demand and sales for pharmaceutical companies. It also funds research and development initiatives, fostering innovation and the introduction of new therapies. Moreover, government spending often includes subsidies and reimbursement programs, making medications more affordable for patients encouraging growth of the market.

Threat:

Generic competition

Patents for branded drugs expire, generic drug makers can produce and sell cheaper versions of these medications, leading to a sharp decline in the sales of the original products. This increased availability of lower-cost alternatives drives down prices across the market, reducing profit margins for both brand-name and generic pharmaceutical companies thereby the presence of generics also forces branded drug manufacturers to invest more in marketing and innovation to differentiate their products, increasing operational costs.

Covid-19 Impact:

The COVID-19 pandemic profoundly impacted the pharmaceuticals market, accelerating innovation and the development of vaccines and treatments. It increased demand for medications, diagnostics, and healthcare supplies, boosting revenues for many companies. However, it also disrupted supply chains, delayed clinical trials, and strained resources. The crisis emphasized the importance of agility and collaboration in the industry, leading to rapid advancements and a renewed focus on global health preparedness and resilience against future pandemics.

The branded drugs segment is expected to be the largest during the forecast period

The branded drugs is expected to be the largest during the forecast period because these drugs, protected by patents, allow pharmaceutical companies to recoup research and development costs and fund further innovation. They often command higher prices, contributing to substantial revenue and profitability for their manufacturers and branded drugs remain crucial for advancing medical treatments and addressing unmet healthcare needs.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is expected to have the highest CAGR during the forecast period owing to the high prevalence of cancer worldwide creates substantial demand for effective treatments, positioning oncology as a top priority for pharmaceutical companies. This focus leads to the development of innovative therapies, including targeted treatments, immunotherapy's, and personalized medicine, which command high prices and generate substantial revenue ensuring sustained growth and innovation within the industry.

Region with largest share:

North America is projected to hold the largest market share during the forecast period North America, particularly the U.S., represents a significant portion of the global pharmaceuticals market. The market is characterized by strong growth due to aging populations, increasing prevalence of chronic diseases, and high demand for innovative treatments. Further the region is a leader in pharmaceutical innovation, with substantial investments in research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period as the Asia-Pacific region is experiencing significant growth due to increasing healthcare needs, rising disposable incomes, and expanding access to healthcare services. Countries like China and India are major contributors to this growth, with their large populations and improving healthcare infrastructure. Local companies are major players in the generic drug market, contributing to the region's growing pharmaceutical industry.

Key players in the market

Some of the key players in Pharmaceuticals market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Novartis International AG, Merck & Co., Inc. (MSD), Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, AstraZeneca, AbbVie Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Gilead Sciences, Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc. and Biogen Inc.

Key Developments:

In July 2024, Johnson & Johnson strengthened pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics. The company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases

In June 2024, Pfizer Inc. and BioNTech received positive CHMP opinion for Omicron JN.1-adapted COVID-19 vaccine in the European Union. The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older

In June 2024, Bayer receives breakthrough therapy designation in China for BAY 2927088 in high unmet need patients with HER2-mutant non-small cell lung cancer. The Center for Drug Evaluation in China has granted breakthrough therapy designation to expedite the development

Product Types Covered:

  • Branded Drugs
  • Generic Drugs
  • OTC (Over-the-Counter) Drugs
  • Biopharmaceuticals
  • Vaccines
  • Other Product Types

Route of administrations Covered:

  • Oral
  • Injectable
  • Topical
  • Inhalation
  • Transdermal
  • Nasal
  • Other Route of administrations

Therapy Areas Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Respiratory Diseases
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Diabetes
  • Other Therapy Areas

End Users Covered:

  • Clinics
  • Hospitals
  • Home Care Settings
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmaceuticals Market, By Product Type

  • 5.1 Introduction
  • 5.2 Branded Drugs
  • 5.3 Generic Drugs
  • 5.4 OTC (Over-the-Counter) Drugs
  • 5.5 Biopharmaceuticals
  • 5.6 Vaccines
  • 5.7 Other Product Types

6 Global Pharmaceuticals Market, By Route of administration

  • 6.1 Introduction
  • 6.2 Oral
    • 6.2.1 Tablets
    • 6.2.2 Capsules
    • 6.2.3 Liquids
    • 6.2.4 Syrups
  • 6.3 Injectable
    • 6.3.1 Intravenous
    • 6.3.2 Intramuscular
    • 6.3.3 Subcutaneous
    • 6.3.4 Infusions
  • 6.4 Topical
    • 6.4.1 Creams
    • 6.4.2 Ointments
    • 6.4.3 Gels
    • 6.4.4 Patches
  • 6.5 Inhalation
    • 6.5.1 Metered-Dose Inhalers
    • 6.5.2 Dry Powder Inhalers
    • 6.5.3 Nebulizers
  • 6.6 Transdermal
  • 6.7 Nasal
  • 6.8 Other Route of administrations

7 Global Pharmaceuticals Market, By Therapy Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Cardiovascular Diseases
  • 7.4 Neurology
  • 7.5 Respiratory Diseases
  • 7.6 Gastrointestinal Disorders
  • 7.7 Infectious Diseases
  • 7.8 Diabetes
  • 7.9 Other Therapy Areas

8 Global Pharmaceuticals Market, By End User

  • 8.1 Introduction
  • 8.2 Clinics
  • 8.3 Hospitals
  • 8.4 Home Care Settings
  • 8.5 Research & Academic Institutes
  • 8.6 Other End Users

9 Global Pharmaceuticals Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Pfizer Inc.
  • 11.2 Johnson & Johnson
  • 11.3 Roche Holding AG
  • 11.4 Novartis International AG
  • 11.5 Merck & Co., Inc. (MSD)
  • 11.6 Bristol-Myers Squibb
  • 11.7 Sanofi
  • 11.8 GlaxoSmithKline
  • 11.9 AstraZeneca
  • 11.10 AbbVie Inc.
  • 11.11 Eli Lilly and Company
  • 11.12 Bayer AG
  • 11.13 Amgen Inc.
  • 11.14 Takeda Pharmaceutical Company Limited
  • 11.15 Boehringer Ingelheim
  • 11.16 Gilead Sciences, Inc.
  • 11.17 Novo Nordisk A/S
  • 11.18 Teva Pharmaceutical Industries Ltd.
  • 11.19 Astellas Pharma Inc.
  • 11.20 Biogen Inc.

List of Tables

  • Table 1 Global Pharmaceuticals Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pharmaceuticals Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Pharmaceuticals Market Outlook, By Branded Drugs (2022-2030) ($MN)
  • Table 4 Global Pharmaceuticals Market Outlook, By Generic Drugs (2022-2030) ($MN)
  • Table 5 Global Pharmaceuticals Market Outlook, By OTC (Over-the-Counter) Drugs (2022-2030) ($MN)
  • Table 6 Global Pharmaceuticals Market Outlook, By Biopharmaceuticals (2022-2030) ($MN)
  • Table 7 Global Pharmaceuticals Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 8 Global Pharmaceuticals Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 9 Global Pharmaceuticals Market Outlook, By Route of administration (2022-2030) ($MN)
  • Table 10 Global Pharmaceuticals Market Outlook, By Oral (2022-2030) ($MN)
  • Table 11 Global Pharmaceuticals Market Outlook, By Tablets (2022-2030) ($MN)
  • Table 12 Global Pharmaceuticals Market Outlook, By Capsules (2022-2030) ($MN)
  • Table 13 Global Pharmaceuticals Market Outlook, By Liquids (2022-2030) ($MN)
  • Table 14 Global Pharmaceuticals Market Outlook, By Syrups (2022-2030) ($MN)
  • Table 15 Global Pharmaceuticals Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 16 Global Pharmaceuticals Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 17 Global Pharmaceuticals Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 18 Global Pharmaceuticals Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 19 Global Pharmaceuticals Market Outlook, By Infusions (2022-2030) ($MN)
  • Table 20 Global Pharmaceuticals Market Outlook, By Topical (2022-2030) ($MN)
  • Table 21 Global Pharmaceuticals Market Outlook, By Creams (2022-2030) ($MN)
  • Table 22 Global Pharmaceuticals Market Outlook, By Ointments (2022-2030) ($MN)
  • Table 23 Global Pharmaceuticals Market Outlook, By Gels (2022-2030) ($MN)
  • Table 24 Global Pharmaceuticals Market Outlook, By Patches (2022-2030) ($MN)
  • Table 25 Global Pharmaceuticals Market Outlook, By Inhalation (2022-2030) ($MN)
  • Table 26 Global Pharmaceuticals Market Outlook, By Metered-Dose Inhalers (2022-2030) ($MN)
  • Table 27 Global Pharmaceuticals Market Outlook, By Dry Powder Inhalers (2022-2030) ($MN)
  • Table 28 Global Pharmaceuticals Market Outlook, By Nebulizers (2022-2030) ($MN)
  • Table 29 Global Pharmaceuticals Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 30 Global Pharmaceuticals Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 31 Global Pharmaceuticals Market Outlook, By Other Route of administrations (2022-2030) ($MN)
  • Table 32 Global Pharmaceuticals Market Outlook, By Therapy Area (2022-2030) ($MN)
  • Table 33 Global Pharmaceuticals Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 34 Global Pharmaceuticals Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
  • Table 35 Global Pharmaceuticals Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 36 Global Pharmaceuticals Market Outlook, By Respiratory Diseases (2022-2030) ($MN)
  • Table 37 Global Pharmaceuticals Market Outlook, By Gastrointestinal Disorders (2022-2030) ($MN)
  • Table 38 Global Pharmaceuticals Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 39 Global Pharmaceuticals Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 40 Global Pharmaceuticals Market Outlook, By Other Therapy Areas (2022-2030) ($MN)
  • Table 41 Global Pharmaceuticals Market Outlook, By End User (2022-2030) ($MN)
  • Table 42 Global Pharmaceuticals Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 43 Global Pharmaceuticals Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 44 Global Pharmaceuticals Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 45 Global Pharmaceuticals Market Outlook, By Research & Academic Institutes (2022-2030) ($MN)
  • Table 46 Global Pharmaceuticals Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.